ERAXIS 100 mg/30mL (Anidulafungin INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION) 100 mg/30mL

ERAXIS 100 mg/30mL is an antifungal medication used to treat serious fungal infections. This lyophilized powder for solution is administered intravenously and contains anidulafungin as the active ingredient.

Strength

100 mg/30mL

Pack Size

30 mL in 1 VIAL, SINGLE-USE (0049-0116-28)

Manufacturer / TM Owner

Roerig

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

ERAXIS 100 mg/30mL is primarily used for the treatment of invasive candidiasis and esophageal candidiasis. It is an antifungal medication that works by inhibiting the growth of fungi. This medication is often prescribed for patients who require intravenous antifungal therapy.

Side Effects

Common effects of ERAXIS 100 mg/30mL may include infusion-related reactions such as fever, chills, and rash. Some patients may also experience gastrointestinal issues like nausea or diarrhea. These effects are generally mild and temporary.

Precautions & Warnings

ERAXIS 100 mg/30mL should be used with caution in patients with a history of hypersensitivity to anidulafungin or similar antifungal agents. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional.

Avoid Interactions

ERAXIS 100 mg/30mL may interact with certain medications, including those metabolized by the liver. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions.

References

Frequently Asked Questions

ERAXIS 100 mg/30mL is used to treat serious fungal infections, such as invasive candidiasis and esophageal candidiasis.

ERAXIS 100 mg/30mL is administered intravenously as a lyophilized powder that is reconstituted into a solution.

Common side effects may include infusion-related reactions like fever, chills, and rash, as well as gastrointestinal issues such as nausea or diarrhea.

ERAXIS 100 mg/30mL may interact with certain medications, so it is important to consult a healthcare provider before combining it with other treatments.

ERAXIS 100 mg/30mL should be used with caution in patients with a history of hypersensitivity to anidulafungin or similar antifungal agents.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.